Evaxion posts $3.7M Q2 loss, advances cancer vaccine pipeline

Evaxion A/S (NASDAQ: EVAX), a Copenhagen-based clinical-stage vaccine company, reported a net loss of $3.7 million for the second quarter ended June 30, 2026, compared to a net loss of $4.8 million in the same period a year earlier, according to a company press release.

Research and development expenses were $2.3 million for the quarter, a slight increase from $2.2 million in the second quarter of 2025. General and administrative expenses fell to $1.5 million from $2.2 million in the year-ago period, primarily due to lower capital market costs. Cash and cash equivalents stood at $14.0 million as of June 30, 2026, down from $18.4 million at the end of the first quarter. The company said its cash runway extends into the second half of 2027.

Total equity declined to $9.5 million as of June 30, 2026, from $17.0 million at December 31, 2025, reflecting net losses recorded in the first half of the year.

On the pipeline front, Evaxion said it plans to present three-year clinical data for its personalized cancer vaccine candidate EVX-01 at the European Society for Medical Oncology Congress in October 2026. The company also presented new preclinical data for EVX-04, an off-the-shelf cancer vaccine targeting acute myeloid leukemia, at the European Hematology Association Congress, and said it expects to submit a regulatory filing for clinical testing of EVX-04 before year-end.

Evaxion also announced EVX-05, a new off-the-shelf cancer vaccine candidate targeting glioblastoma, developed in part through collaboration with Duke University School of Medicine. New data for its cytomegalovirus vaccine candidate EVX-V1 was presented at the International Herpesvirus Workshop in July 2026.

The company received the 2026 Prix Galien UK Award for best digital health solution for its AI-Immunology platform in June.

CEO Helen Tayton-Martin said the pipeline expansion reflects the platform's ability to identify novel cancer targets, adding that validation of the platform is important for potential partnerships.

You May Also Be Interested In

• ADARx Pharmaceuticals files for proposed IPO
• USA Rare Earth (USAR) files $1.25B mixed shelf
• Seagate board member Arumugavelu to step down at annual meeting